Annette G. Beck-Sickinger
Annette G. Beck-Sickinger
Annette G. Beck-Sickinger studied chemistry and biology at the University of Tübingen (Germany) and received her Ph. D. in organic chemistry. She was post-doc with E. Carafoli (Laboratory of Biochemistry, ETH Zürich) and appointed as assistant professor of Pharmaceutical Biochemistry at ETH Zürich. Since October 1999, she is full professor of Biochemistry and Bioorganic Chemistry at the University of Leipzig. She spent a sabbatical at Vanderbilt University (Nashville, TN) as visiting professor.
Annette Beck-Sickinger was a member of the Board of the German Chemical Society (Gesellschaft Deutscher Chemiker, 2004-2012; Vice-President 2006-2008) and of the DFG panel „Biochemistry“ (2004-2012). Since 2017 she is member of the Board of the German Society for Biochemistry and Molecular Biology (gbm) and since 2019 President. She has been awarded with many prices including the Leonidas Zervas Award of the European Peptide Society, the gold medal of the Max-Bergmann-Kreis (2009), the Leipzig Science Award (2016), the Albrecht Kossel Award of Biochemistry of the GDCh (2018) and the Du Vigneaud Award of the American Peptide Society (2019). She was honoured with the membership of the Saxonian Academy of Science in 2009, and in 2012, she became an elected member of the German National Academy of Sciences Leopoldina. In 2017, she was awarded with the Saxonian Order of Merit.
Her major reseach fields include structure-activity-relationships of peptide hormones and G protein coupled receptors as well as protein modification to study function and interaction. A tight connection of chemical methods, bioorganic synthesis and molecular biology tools, including cloning, receptor mutagenesis, protein expression and cell biochemistry is applied. Her interests include further the identification of novel targets, novel therapeutic concepts and innovative approaches to modify proteins as well as concepts for improved enzyme catalysis and biomaterials.
Dame Margaret Brimble
Dame Margaret Brimble
Dame Margaret Brimble FRS is the Director of Medicinal Chemistry and a Distinguished Professor at the University of Auckland where her research program focuses on the synthesis of bioactive natural products, antimicrobial peptides, cancer vaccines, glycopeptides, self-assembling peptides and peptidomimetics. She has published >475 papers, 70 reviews and is an inventor on >50 patents. In 2018 she was elected a Fellow of the Royal Society London, awarded the Royal Society of Chemistry George and Christine Sosnovsky Award in Cancer Therapy and conferred the Queens Honour Dame Companion of the New Zealand Order of Merit (DNZM). She won the 2016 Marsden Medal, the 2012 RSNZ Rutherford (NZ’s top science prize), MacDiarmid and Hector Medals, the 2011 Royal Australian Chemical Institute Adrien Albert Award, the 2010 RSC Natural Products Award, the 2007 L’Oreal-UNESCO Women in Science laureate in Materials Science for Asia-Pacific, a 2015 IUPAC Distinguished Women in Chemistry/Chemical Engineering Award. She is an Associate Editor for Organic Letters, Past-Associate Editor for Organic and Biomolecular Chemistry, Past-President of IUPAC Organic and Biomolecular Division III, Past-President of the International Society of Heterocyclic Chemistry and Past-Chair of the Rutherford Foundation RSNZ. She discovered the first drug named “trofinetide” to treat Rett Syndrome and Fragile X Syndrome that is in phase III clinical trials with Neuren Pharmaceuticals and Acadia Pharmaceuticals. Margaret also co-Founded the spin-out company SapVax with US$6 million funding from BioMotiv USA to take self-adjuvanting cancer vaccines based on a novel chemistry platform, to clinical trial (see: https://sapvaxllc.com).
Julio A. Camarero
Julio A. Camarero
Dr. Camarero's research develops new technologies to find novel compounds that block bacteria from causing disease while uncovering a new generation of therapeutics and diagnostics through development of viable antibody substitutes. Drug pipelines are currently running on empty as synthetic and natural small-molecule libraries have already been screened, and new chemical entities have not been identified. Recognizing that nature has had millions of years to develop new compounds, Camarero's work exploits the potential of naturally occurring biomecules, using modern chemistry to tweak these compounds to their maximize affinity for a given target.
In most cases, antibodies, like other proteins, cannot be taken orally as they are large, unstable molecules that are broken down when ingested. Most antibodies, therefore, must be administered intravenously. Furthermore, they are difficult to produce, making them more costly than other oral alternatives. Camarero is looking for the next generation of biologics that are stable, cheaper, and orally ingestible. He does this by using a particular family of peptides, called cyclotides, as a scaffold or base which can be modified to a stable antibody substitute.
In the attempt to develop new approaches for therapeutics and diagnostics, Camarero uses these cyclotides as protease inhibitors (preventing the breakdown of proteins) which can be adapted to specific molecular targets active in cancer and viral and microbial diseases. Camarero can instruct individual cells to make these different peptides, creating collections of millions of cells with unique peptides very quickly to constitute a molecular library. Then he challenges the cell population with the target molecule and uses high throughput techniques to identify the best peptide binders. Next, he screens the cells to see which function against the target, sorting the active cells according to attributes. This allows Camarero to rapidly screen billions of compounds, identifying about a hundred potential candidates at a time to take to drug testing and development.
This research will ultimately help detect cancers and other diseases which exhibit unique protein biomarkers that can become cyclotide targets and develop cyclotides as stable, new, biologically-based, next-generation therapeutics in an extremely efficient, cost-effective manner.
Dr. Camarero started his studies in chemistry at the University if Barcelona (Spain), received his Master degree in 1992, and finished his PhD thesis there in 1996. Afterwards he joined the group of Professor Tom W. Muir at The Rockefeller University as a Burroughs Wellcome Fellow where he contributed to the development of new chemoselective ligation techniques for the chemical engineering of proteins. In 2000, he moved to the Lawrence Livermore National Laboratory as a Distinguished Lawrence Fellow where he became staff scientist and head of laboratory in 2003. He finally joined the University of Southern California in 2008 where he is professor of pharmacology and pharmaceutical sciences.
His current research interests are focused in the development of new bioorganic approaches using protein splicing and synthetic protein chemistry for studying biological processes involved in bacterial pathogenicity and how can be modulated or inhibited by small molecules. Dr. Camarero has authored over 40 peer-reviewed publications and four invited book chapters.
Philip Dawson is a Professor in the Department of Chemistry, Scripps Research in La Jolla, CA and Dean of the Skaggs Graduate School of Chemical and Biological Sciences. He received an A.B. (1992) in Chemistry from Washington University, and Ph.D. (1996) from Scripps Research under the guidance of Steve Kent. After pursuing postdoctoral work at Caltech, he returned to Scripps as an Assistant Professor. He has served as President of the American Peptide Society, the Board of Directors for FASEB and co-chaired the 22nd American Peptide Symposium and the 2016 GRC. He has published over 160 papers, and has been honored with an Alfred P. Sloan Foundation fellowship, the Vincent du Vigneaud Award, the Max Bergmann Kreis Gold Medal, the Zervas Award and the RSC MedImmune Protein and Peptide Science Award.
Kyoto University, Japan
Shiroh Futaki obtained his Ph.D. in 1989 from Kyoto University, Japan. Following his appointment as a Research Associate and an Associate Professor at the University of Tokushima, he moved to Kyoto University in 1997. Meanwhile, he spent 16 months (1989-1991) in the US as a Postdoctoral Associate in the Department of Biochemistry, Rockefeller University. He has been a Professor of Biochemistry at the Institute of Chemical Research, Kyoto University, since 2005. He is now the Vice President of The Japanese Peptide Society.
Prof. Dr. Ernest Giralt is a Group Leader at the Institute for Research in Biomedicine (IRB Barcelona) where is also the Head of the Chemistry & Structural Biology Node. He is also a professor at the University of Barcelona.
Prof. Dr. Giralt is an internationally renowned scientist in the field of peptide synthesis, medicinal chemistry, structure determination and NMR (Nuclear Magnetic Resonance). Besides, he is an expert on the design of therapeutic ligands for interaction with protein surfaces. He has received several awards, among others the Dimitrios Theodoropoulos Award (2010) and the Josef Rudinger Memorial Lecture Award (2014), both from the European Peptide Society; the Novartis Chemistry Lectureship Award (2011); the National Research Award (2011) from the Ministerio de Ciencia e Innovación (Spain); the Max Bergmann Medal (2014); and the 'Ciutat de Barcelona' Award (2015).
His major interests lie in the study of complex molecular recognition processes, with emphasis on the design of specific ligands for interaction with protein surfaces, related to possible therapeutic uses. This includes studies concerning new drug delivery systems for the treatment of central nervous system pathologies.
Juan B. Granja
Juan B. Granja
Juan R. Granja received his PhD in chemistry from the University of Santiago de Compostela under the supervision of Professors Antonio Mouriño and Luis Castedo. After his postdoctoral work with Prof. Barry M. Trost at Stanford University, he returned to the University of Santiago as assistant professor. He was appointed Associate professor in 1996. He has been visiting professor at the Scripps Research institute at la Jolla for several times since his first visit in 1992. He is since 2006 Full Professor at the University of Santiago de Compostela. He is at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS), where he leads a research group focused on the design and synthesis of tubular-shaped nanomaterials for biological applications. In 2014 he was awarded with the Ignacio Ribas medal by the Organic Chemistry Group of the Spanish Royal Society of Chemistry (RSEQ).
Paula A. C. Gomes
Paula A. C. Gomes
Paula A. C. Gomes (http://orcid.org/0000-0002-6018-4724; https://www.fc.up.pt/pessoas/pgomes/) is an Associate Professor, with Habilitation in Chemistry, at the Department of Chemistry and Biochemistry of the Faculty of Sciences of the University of Porto (FCUP), Portugal. She graduated in Chemistry at the same University, in 1993, where she also carried out her M.Sc. in Chemistry, under the guidance of Professors Maria Joaquina Amaral-Trigo and Maria Isabel Oliveira Santos, on the topic of dipeptide-based prodrugs of classical sulfonamide antibiotics. She then pursued her Ph.D. in Chemistry at the University of Barcelona, Spain (1997–2000), on the topics of solid phase peptide synthesis and use of surface plasmon resonance sensors for the study of peptide antigens–antibody interactions, under the guidance of Professor David Andreu. She now leads “ORCHIDS”, a Bioorganic Chemistry-oriented research group, where her main research goals include (i) drug rescuing, repurposing and repositioning, mainly applied to antimalarial drugs, (ii) antimicrobial peptides, (iii) peptide-based drug delivery strategies, and (iv) peptide-grafted biomaterials. She is also the coordinator of “POP-UP”, the peptide synthesis facility set up at FCUP, and the first of its kind in Portugal.
At present, Paula Gomes is one of the Vice-Presidents of the Medicinal Chemistry Division of the Portuguese Chemistry Society (SPQ), the Secretary of the European Peptide Society (EPS), and the National Representative of Portugal at Division VII – Chemistry and Human Health, of the International Union for Pure and Applied Chemistry (IUPAC), for which she was recently appointed as an Associate Member for 2020-2021.
Christian P. R. Hackenberger
Christian P. R. Hackenberger
Christian P. R. Hackenberger completed his graduate studies in chemistry at the universities of Freiburg and UW Madison and his doctoral studies in 2003 at the RWTH Aachen. After a postdoctoral position at MIT with Barbara Imperiali, he started his own group at the Freie Universität Berlin in 2005 funded by the German Science Foundation in the Emmy Noether Program and the Boehringer-Ingelheim Foundation within the Plus 3 award. In 2012, he was appointed Leibniz-Humboldt Professor for Chemical Biology at the Leibniz-Research Institute for Molecular Pharmacology and the Humboldt Universität zu Berlin. His group works on the development of new chemoselective and bioorthogonal reactions, the identification and analysis of novel post-translational modifications, the engineering of protein-based pharmaceuticals and novel approaches to functional protein synthesis and delivery, in particular for the labeling and modification of different antibody formats. He is co-founder of the start-up 'Tubulis Technologies', a newly established company, which ventures into engineering better tolerable cancer drugs based on protein- and antibody-drug conjugates.
Knud J. Jensen
Knud J. Jensen
Knud J. Jensen obtained a Ph. D. degree in synthetic bioorganic chemistry with professor Morten Meldal in 1992, after which he did postdoctoral research with professor George Barany, University of Minnesota. He became assistant professor at the Technical University of Denmark in 1997 and associate professor at KVL in Copenhagen in 2001, which in 2007 became part of the University of Copenhagen. The same year he was promoted to full professor in nanobioscience. He is now a full professor at the Department of Chemistry, University of Copenhagen. He is the co-author of >150 peer-reviewed publications, as well as numerous book chapters and proceedings. In 2010, he was the co-chair of the 31st European Peptide Symposium, which was held in Copenhagen. He was awarded the prestigious Zervas Award of the European Peptide Society in 2012. His research covers a broad range of topics at the interface between synthetic chemistry, biology, biophysics, medicinal chemistry, and nanobioscience
Department of Bioscience and Biotechnology
Dr. Yangmee Kim is a Professor at the Department of Bioscience and Biotechnology, Konkuk University, Korea. She received a BS in Chemistry in 1984 from Yonsei University, MS in Physical Chemistry in 1986 from Yonsei University. She got Ph.D under the direction of Professor James H. Prestegard in Biophysical Chemistry, Yale university in 1990 with a NMR study on motional Effects on Structural Data for Acyl Carrier Protein from E. coli and Spinach . She carried out postdoctoral research on NMR spectroscopy at Yale University until 1991, and then she joined Konkuk Universityh as an Assistant Professor in 1992. Based on structure-activity relationship, Dr. kim is developing potent antimicrobial peptide (AMP) which can be a new type of antibiotics to fight infectious diseases and solve Multi Drug Resistance problem. She studies structure and dynamics of proteins in fatty acid synthase (FAS) of Multi-drug resistant pathegens and she develops antibiotics targeting MDR FAS using NMR spectroscopy and in-silico screening. She designs new therapeutic antibiotics and peptides with broad spectrum antibacterial activities as well as a range of immunomodulatory activities to treat infections and sepsis. Currently, Dr. Kim is a president of Korean Peptide and Protein Society and is a co-chair of 2022 International Conference on Magnetic Resonance in Biological Systems (ICMRBS) which will be held in Seoul.
Glenn F. Kin
Glenn F. Kin
Glenn did his PhD at the University of Sydney before postdoctoral studies at the University of Oxford. After academic stints at the University of Sydney and the University of Connecticut Health Center, he joined the Institute for Molecular Bioscience at The University of Queensland in 2007. Professor King is a pioneer in the field of venoms-based peptide drug discovery, in particular the development of drugs and environmentally-friendly insecticides derived from spider venoms. Professor King’s early work on venoms lead to him to found an agricultural biotechnology company (Vestaron Corporation) that is developing bee-safe, eco-friendly peptidic bioinsecticides. Professor King’s current research is focused on the development of peptide drugs to treat chronic pain, epilepsy, and stroke. His laboratory at the University of Queensland maintains the largest collection of venoms in the world, comprising more than 700 venoms from ants, assassin bugs, caterpillars, centipedes, cone snails, scorpions, spiders, and wasps. Professor King has published 3 books, 19 book chapters, and more than and 250 peer-reviewed articles in international scientific journals. Glenn is a former President of the Australian Society for Biophysics and former Chair of the Australian & New Zealand Society for Magnetic Resonance. He has served on the editorial board of numerous journals and is currently Editor-in-Chief of the journal Toxicon.
Marcelo J. Kogan
Marcelo J. Kogan
Prof. Dr. Marcelo J. Kogan was born in Buenos Aires , Argentina in 1964. He is Professor at the Department of Pharmacology and Toxicology of the School of Pharmacy at the University of Chile and Principal Investigator at the Advanced Center for Chronic diseases (ACCDiS). He is the Coordinator of the Pharmaceutical Sciences Program of the University of Chile. He is the Director of the Laboratory of NANOMEDICINE AND NANOTHERANOSTICS at this center. He is Biochemist and Pharmacist at the University of Buenos Aires and PhD in Organic Chemistry from the same University. He did his postdoctoral research at the Institut of Biomedical Research Barcelona in the field of peptides. His interest is centered on applications of nanobiomaterials and peptides in biomedicine for diagnosis and treatment of conformational diseases including drug delivery, Alzheimer, Cancer and cardiovascular diseases. He is a pioneer in the field of use nanoparticles for disaggregation of amyloids.
Beate Koksch received a Ph.D. degree from University Leipzig and pursued postdoctoral studies at TSRI La Jolla and postdoctoral lecture qualification at University Leipzig under the mentorship of Klaus Burger. She has been Professor of Organic and Natural Product Chemistry at Freie Universität Berlin since 2004. Her group investigates fluorinated amino acids in the context of peptides and proteins, studies complex folding mechanisms in neurodegenerative diseases, develops new peptidic multivalent scaffolds, catalytically active peptide-nanoparticle conjugates and foldamers and applies phage-display technology to find binding partners for artificial amino acids and peptides. Her group has published more than 150 scientific papers. She has been the organizer of the 8th Peptide Engineering Meeting 2018 and the 10th German Peptide Symposium 2011, both held in Berlin, Germany.
William D. Lubell
William D. Lubell
Professor William D. Lubell has been actively advancing the fields of medicinal chemistry and peptide science through the development of seminal methods to create and employ peptide and peptidomimetic prototypes that target and modulate biologically relevant receptors for drug discovery (www.wdlubellgroup.com). After receiving B.A. (Columbia College, 1984) and Ph.D. (U. of California, Berkeley, 1989, with Professor Henry Rapoport) degrees, Lubell was a Japan Society for the Promotion of Science Fellow (1990-1991) in the laboratory of Professor Ryoji Noyori at Nagoya U., Japan, before joining the Department of Chemistry at the U. de Montréal in 1991. Co-author of >250 scientific publications, former Associate Editor of Organic Letters (2005-2018), editorial board member of journals in the biomedical sciences, and innovator of intellectual property to launch the Canadian start-up companies Mperia Therapeutics and Rytvel Biotech, his honors include the Boehringer Ingelheim Young Investigator Award, the DuPont Canada Educational Aid Grant, the Danish National Bank Award, the Merck Therapeutic Research Award, the 2013 CSC Bernard Belleau Award for achievements in medicinal chemistry, and in 2018, the Teva Canada Limited Biological and Medicinal Chemistry Lectureship Award. Originator of Molecules of Life (www.moleculesoflife.ca), Lubell explores experiential education techniques to teach elementary school students about molecules.
Maria Luisa Mangoni
Maria Luisa Mangoni
Maria Luisa Mangoni graduated in Biological Sciences cum Laude in 1996 at Sapienza University of Rome. She then moved to Karolinska Institute, Stockholm, in the laboratories of Professor Hans G. Boman, where she acquired expertise and familiarity with microbiological and immunological techniques. In 2003, she received her PhD in Biochemistry at Sapienza University and in 2012 she was appointed as Associate Professor of Biochemistry at the Department of Biochemical Sciences, same University. She has more than 15-years experience in the field of antimicrobial peptides (AMPs) with special reference to structure-function studies of membrane-active AMPs from amphibian skin or their synthetic analogs. Her major research interest is the development of these molecules as new anti-infective agents for treatment of skin/lung/ocular surface infections, while limiting the induction of resistance (http://www.marialuisamangoni.it/). Beside exploring the mechanism of microbicidal activity of AMPs, she has recently focused on their further biological functions, with particular attention to the wound healing activity. Furthermore, by means of nanotechnological approaches, she is investigating the effectiveness of AMPs’ conjugation to nanoparticulate systems or to biomaterials in protecting the peptides from proteolytic degradation as well as in assisting their delivery to the target site at effective concentrations.
The main objectives of her current scientific research include the development of (i) new inhalable formulations to optimize the pulmonary release of AMPs; (ii) antimicrobial medical devices, such as peptide-coated contact lenses, to prevent the establishment of eye infections; (iii) peptide-based nano-formulations to accelerate wound-healing of the corneal/bronchial epithelium or the skin. She is member of the Editorial Board of several journals including Biochimica et Biophysica Acta Biomembranes; Associate Editor of “Frontiers in Chemistry; section Biological Chemistry” and Section Editor of “Antibiotics”. She is the Italian Representative at the European Peptide Society and has more than 100 publication in international peer-reviewed and indexed journals.
Les Miranda is Executive Director at Amgen, Inc. Prior to joining Amgen in 2004, Les gained his Ph.D. in peptide and protein chemistry from the University of Queensland, Australia. Les held a research position at the Carlsberg Laboratory in Copenhagen, Denmark, and then served as an Associate Director at Gryphon Therapeutics in South San Francisco where he pioneered work in polymer conjugated non-ribosomal erythropoietic proteins for clinical development. At Amgen, he has held various positions of increasing responsibility. This includes leadership of Hybrid Modality Engineering, Structural Biology (X-ray crystallography & cryo-EM), & Molecular Modeling. In this role, Les led cross-functional teams across Amgen’s North American research sites with primary responsibility for advancing the early pipeline in Amgen’s cardiometabolic, neuroscience, inflammation, and oncology therapeutic areas. This included supporting the delivery of a diverse set of clinical candidates across peptide, protein, antibody, small molecule, & siRNA related modalities. Over the years, Les has also led Medicinal Chemistry Research Technologies and various initiatives that developed innovative discovery platforms & business processes. Most recently, Les leads the Pre-Pivotal Attribute Sciences group responsible for partnering with other Attribute Sciences, Process Development, Product Quality and Research & Development functions to advance Amgen’s polymodal portfolio from the pre-clinical phase to IND filing. During his career, Les has authored more than 60 original peer reviewed publications and is an inventor on more than 20 published/issued patents.
Tom W. Muir received his B.Sc in Chemistry in 1989 and Ph.D. in Chemistry in 1993 from the University of Edinburgh. After postdoctoral studies with Stephen B.H. Kent at the Scripps Research Institute, he joined the faculty at the Rockefeller University in New York City in 1996. In 2011, Dr. Muir joined Princeton University as the Van Zandt Williams, Jr. Class of ’65 Professor of Chemistry. He currently serves as Chair of the Princeton Department of Chemistry. He has published over 200 scientific articles in the area of chemical biology and is best known for developing methods for the preparation of proteins containing unnatural amino acids, posttranslational modifications and spectroscopic probes. These approaches are now widely employed in academia and industry. His currents interests lie in the area of epigenetics, where he tries to illuminate how chemical changes to chromatin are linked to different cellular phenotypes. Professor Muir has won a number of honors for his research, including; the Burroughs-Wellcome Fund New Investigator Award, the Pew Award in the Biomedical Sciences, the Alfred P. Sloan Research Fellow Award, the Leonidas Zervas Award from the European Peptide Society, the Irving Sigal Award from the Protein Society, the Vincent du Vigneaud Award in Peptide Chemistry, the Blavatnik Award from the New York Academy of Sciences, the Jeremy Knowles Award from the Royal Society of Chemistry, the Arthur C. Cope Scholar Award from the American Chemical Society, the Breslow Award in Biomimetic Chemistry from the American Chemical Society, and the E.T. Kaiser Award in Protein Chemistry from the Protein Society. Dr. Muir is a Fellow of American Association for the Advancement of Science, the Royal Society of Chemistry and the Royal Society of Edinburgh
Anna Maria Papini
Anna Maria Papini
After completing an International PhD in 1990, under the supervision of Prof. Luis Moroder of the Max Planck Institut fuer Biochemie, A.M. Papini has been appointed Professor of Bioorganic Chemistry in 2002. Since 2014 she is Director of the Research Unit PeptLab@UNIFI associating the Departments of Chemistry & NEUROFARBA, Section of Pharmaceutical Sciences at the University of Florence in Italy and of the joined platform PeptLab@UCP at the Université Paris-Seine (France) that she contributed to found in 2001 and 2013 respectively (www.peptlab.eu). Recently in PeptLab@UCP she launched the first KgLab facility in an European academic environment, funded by the Region Ile de France.
In 2008, she was awarded with the L. Zervas of the European Peptide Society and 1st D. Theodoropoulos of the Hellenic Peptide Society. She has been Laureate of the “Chaire d’Excellence” 2009-2014 of the French ANR and in 2019 she has been awarded with the Rita Levi Montalcini Prize for binational Israeli-Italian cooperation for their common research project aimed to the role of aberrant modifications on peptide antigens in autoimmunity. In 2011-2020, she has been nominated EPS Executive Committee member acting as treasurer and for 2019-2025 she has been elected APS councilor. Since 2013 she is delegate of the International Affairs and Erasmus Program of the School of Sciences of the University of Florence. She chaired with Phil E. Dawson the 2016 Gordon Research Conference “Crossing Barriers by Peptide Science for Health and Wellness” and she has been nominated Chair of the next 14th International Peptide Symposium/37th European Peptide Symposium that will organise with Prof. Paolo Rovero in Florence (Italy) on August 28-September 3, 2022. She is cofounder of the first spin-off of the University of Florence EspiKem Srl, launched in 2003, of the start-up Toscana Biomarkers Srl (2007-2014) and for her activity in technology transfer she got in 2009 the Frost & Sullivan Excellence in Research Award in European autoimmune disease diagnostics market & Vespucci Award of Regione Toscana for the perspectives of development of the company aimed to R&D of peptide-based diagnostics for autoimmune diseases. Since 2017 she founded and acts as scientific coordinator of PeptFarm joining PeptLab@UNIFI and Fabbrica Italiana Sintetici (FIS, Italy) to develop large-scale synthesis of peptide-drugs in the new Facility MoD&LS, incubated in the Centre of Competences of the University of Florence. Her main research interests are in glyco-peptides and -proteins for chemical immunology studies and in any aberrant modification triggering the immune system, developing antibodies. She has always been strongly involved in translational research projects in cooperation with clinicians, with a special attention to possible industrial applications, more recently in cosmeceutics.
Christina Schroeder received her MSc in Chemistry from University of Kalmar, Sweden and a PhD in Pharmacology from the University of Queensland working on the development of an omega-conotoxin pharmacophore. She then joined Professor Philip Dawson’s laboratory at The Scripps Research Institute, La Jolla, USA to work on developing palmitoylated peptides as chaperones for infantile Batten disease, subsequently moved to the University of New South Wales in Sydney where she worked on the multimerisation of large proteins via disulfide bonds and in 2011 she was recruited back to UQ to work on the structural biology and synthesis of disulfide-rich plant- and venom-derived peptides with Prof David Craik. In 2014 she started her independent research career and in 2016 she was awarded an Australian Research Council Future Fellowship focussing her research on discovery and design of bioactive disulfide-rich peptides as tools and leads for ion channel pharmacology and novel pain therapeutics.
Thomas R. Ward
Thomas R. Ward
Thomas Ward received his diploma in Chemistry in 1987 from the University of Fribourg and his PhD from the ETH Zürich. He then joined the group of Prof. R. Hoffmann at Cornell University as a postdoctoral fellow to work on qualitative MO theory. After a second postdoc at the University of Lausanne, he moved to Berne to undertake his independent career in 1993. In 2000, he moved to University of Neuchâtel and in 2008 to the University of Basel. His research focuses on artificial metalloenzymes and bio-nanotechnology.
Thomas Ward was awarded the ETH Medaille (1991), the A. Werner Fellowship (1993) as well as the A. Werner Prize (1998), a Swiss National Science Foundation Professorship (2000) and the RSC award in BioInorganic Chemistry (2017). he was awarded an advanced ERC grant to realize his DrEAM: the Directed Evolution of Artificial Metalloenzymes.